Pigment epithelium-derived factor (PEDF): drug developmental challenges ahead for a budding anti-angiogenic.
One of the most potent anti-angiogenic biological discovered to date, pigment epithelium-derived factor (PEDF) is fast becoming an exciting and promising lead candidate. Recent studies have shown that even shortened versions of the protein can serve as therapeutic agents with similar activity as the parent molecule. The next obvious challenge is to find ways to deliver this molecule in vivo with enhanced pharmacodynamics and reduced toxicity. Several methods to achieve this are proposed.
Dass
C R
CR
Department of Orthopaedics, St. Vincent's Hospital, Melbourne, Australia. crispin.dass@svhm.org.au
Choong
P F M
PF
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D016503:Drug Delivery Systems; D015195:Drug Design; D005136:Eye Proteins / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000473:pathology* / Q000517:prevention & control; D009414:Nerve Growth Factors / Q000008:administration & dosage / Q000494:pharmacology*; D015843:Serpins / Q000008:administration & dosage / Q000494:pharmacology*; D000099174:Pigment Epithelium-Derived Factor
D020533:Angiogenesis Inhibitors; D005136:Eye Proteins; D009414:Nerve Growth Factors; D015843:Serpins; D000099174:Pigment Epithelium-Derived Factor